Dr. Evens on the Design of a Retrospective Analysis Evaluating Salvage Regimens in R/R Hodgkin Lymphoma

In Partnership With:

Partner | Cancer Centers | <b>RWJBarnabas Health and Rutgers Cancer Institute of New Jersey</b>

Andrew M. Evens, DO, MSc, discusses the design of a retrospective analysis evaluating in relapsed/refractory classic Hodgkin lymphoma.

Andrew M. Evens, DO, MSc, associate director, Clinical Services, Rutgers Cancer Institute of New Jersey, system director, Medical Oncology, oncology lead, Combined Medical Group, RWJBarnabas Health, associate vice chancellor, Clinical Innovation and Data Analytics, Rutgers Biomedical and Health Sciences, discusses the design of a retrospective analysis evaluating in relapsed/refractory classic Hodgkin lymphoma (cHL).

Data from the real-world retrospective analysis, which was conducted across 12 institutions in the United States, were presented during the 2021 ASH Annual Meeting and Exposition, Evens said. The rationale was to examine comparative outcomes of conventional salvage therapies, such as platinum-based chemotherapy,vs novel targeted salvage regimens in patients with cHL prior to autologous stem cell transplant (ASCT), Evens explains.

Overall, 853 patients that underwent ASCT who were eligible for this study and patients received varied induction therapy regimens, Evens continues. Additionally, prior to ASCT, most patients received 1 prior therapy; however, some groups received additional prior therapies before ASCT, Evens concludes.